Premium
TREATMENT OF MINERALOCORTICOID‐RESISTANT RENAL HYPERKALEMIA WITH HYPERTENSION (TYPE II PSEUDOHYPOALDOSTERONISM)
Author(s) -
WAYNE V. S.,
STOCKIGT J. R.,
JENNINGS G. L.
Publication year - 1986
Publication title -
australian and new zealand journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 0004-8291
DOI - 10.1111/j.1445-5994.1986.tb01154.x
Subject(s) - medicine , hyperkalemia , pseudohypoaldosteronism , endocrinology , blood pressure , mineralocorticoid , aldosterone , thiazide , plasma renin activity , metabolic acidosis , acidosis , renin–angiotensin system
A 16 year old girl with the rare syndrome characterised by hypertension, hyperkalemia, and acidosis was treated with a range of drugs, including thiazides, frusemide, and beta‐adrenoceptor antagonists. None of the agents normalised the hypertension and biochemical abnormalities. Best results were obtained with methyclothiazide in full dosage, which normalised the blood pressure, serum potassium level, and bicarbonate level in the face of increased plasma renin activity. Empirical treatment with thiazides is the most satisfactory method for long term management.